Abstract 122P
Background
Cribriform (cbf) morphology has been shown in carcinomas from various organs, including prostate and breast, to be associated with worse patient outcomes and unique molecular features. We sought to examine the multimodal data from the landmark Cancer Genome Atlas (TCGA) study to clarify molecular and prognostic factors associated with cbf morphology in colorectal adenocarcinomas.
Methods
We retrospectively analyzed the available TCGA CRC cohort (n=594). Clinicopathological, digital slides, and molecular data were extracted. Cases with insufficient clinical data, no diagnostic slides, or poor slide quality were excluded. TCGA coded data, pathology reports, and digital diagnostic slides were reassessed by one gastrointestinal pathologist and a resident. Cbf morphology was graded using five categories based on prostate cribriform studies: (0) no-cribriform, (1) loose cribriform, (2) small cribriforming glands, (3) diffuse large cribriform, and (4) intraductal carcinoma of the prostate-like. Cases were grouped into cbf 'low' (0-1) and cbf 'high' (2-4) groups, which were correlated with clinicopathological, histological and molecular features. Immune infiltration was characterized by cell type fraction. An adjusted α = 0.05 for statistical significance was used for all tests.
Results
573 CRC cases were included. Cbf 'high' CRCs (159/573) were associated with more left-sided tumors (p=0.049), metastatic diseases (p=0.0001), less MSI-H (p=0.003), and different aneuploidy and fraction genome altered (p=0.003-0.008). Cbf 'high' vs 'low' tumors did not show a significant difference in grading distribution. T and N staging were not associated with cbf morphology. By cell fraction, cbf ‘high’ CRCs showed an immune infiltrate with increased regulatory T cells (p<0.0001) but decreased memory B cells (p=0.046), M2 macrophages (p<0.0001), neutrophils (p=0.018), resting dendritic cells (p=0.046), compared with cbf ‘low’ CRCs. Cbf 'high' tumor morphology was associated with worse overall survival outcomes by log-rank testing (p=0.037).
Conclusions
Cribriform morphology in colorectal adenocarcinoma TCGA cases was associated with poorer outcomes and distinct transcriptomic immune profiling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Q-H. Trinh.
Funding
Fonds de recherche Santé Québec.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract